While some groups have reported low expression of TIMP2 in primary ovarian tumors [38], others have seen increased TIMP2 expression in ovarian cancer tissues, suggesting that TIMP2 contributes to tumor progression, in part through the activation of pro-MMP2 and inhibition of anti-tumor activities of MMPs [39], [41]. Here, MMP2 is linked to ovarian carcinoma.